117 related articles for article (PubMed ID: 6339094)
1. High-dose melphalan and autologous bone marrow transplant for relapsed acute leukaemia.
Maraninchi D; Abecasis M; Gastaut JA; Sebahoun G; Cahn JY; Hervé P; Novakovitch G; Carcassonne Y
Cancer Chemother Pharmacol; 1983; 10(2):109-11. PubMed ID: 6339094
[TBL] [Abstract][Full Text] [Related]
2. High-dose melphalan with or without marrow transplantation: a study of dose-effect in patients with refractory and/or relapsed acute leukemias.
Maraninchi D; Pico JL; Hartmann O; Gastaut JA; Kamioner D; Hayat M; Mascret B; Beaujean F; Sebahoun G; Novakovitch G
Cancer Treat Rep; 1986 Apr; 70(4):445-8. PubMed ID: 3516394
[TBL] [Abstract][Full Text] [Related]
3. Repeated courses of high dose melphalan and unpurged autologous bone marrow transplantation in children with acute non-lymphoblastic leukemia in first complete remission.
Michel G; Maraninchi D; Demeocq F; Perrimond H; Blaise D; Gaspard MH; Stoppa AM; Gastaut JA; Lepeu G; Novakovitch G
Bone Marrow Transplant; 1988 Mar; 3(2):105-11. PubMed ID: 3048474
[TBL] [Abstract][Full Text] [Related]
4. High dose melphalan and total body irradiation with autologous marrow rescue in childhood acute lymphoblastic leukaemia after relapse.
Schroeder H; Pinkerton CR; Powles RL; Meller ST; Tait D; Milan S; McElwain TJ
Bone Marrow Transplant; 1991 Jan; 7(1):11-5. PubMed ID: 2043872
[TBL] [Abstract][Full Text] [Related]
5. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. The Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplantation Group.
Bonetti F; Zecca M; Pession A; Messina C; Montagna D; Lanino E; Fagioli F; Santoro N; Prete A; Cesaro S; Rondelli R; Giorgiani G; De Stefano P; Locatelli F
J Clin Oncol; 1999 Dec; 17(12):3729-35. PubMed ID: 10577844
[TBL] [Abstract][Full Text] [Related]
6. Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region Lymphoma Group.
Taylor PR; Jackson GH; Lennard AL; Lucraft H; Proctor SJ
Br J Cancer; 1993 Feb; 67(2):383-7. PubMed ID: 8431371
[TBL] [Abstract][Full Text] [Related]
7. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.
Seymour LK; Dansey RD; Bezwoda WR
Br J Cancer; 1994 Sep; 70(3):526-30. PubMed ID: 8080741
[TBL] [Abstract][Full Text] [Related]
8. High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML.
O'Meara A; Pabst T; Heim D; Gerull S; Bucher C; Halter J; Arber C; Rovò A; Tichelli A; Gratwohl A; Stern M
Bone Marrow Transplant; 2011 May; 46(5):636-40. PubMed ID: 20697364
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation.
Cornbleet MA; Corringham RE; Prentice HG; Boesen EM; McElwain TJ
Cancer Treat Rep; 1981; 65(3-4):241-4. PubMed ID: 7016319
[TBL] [Abstract][Full Text] [Related]
10. Autologous bone marrow transplantation for acute myeloid leukaemia in children using total body irradiation and melphalan as conditioning regimen.
Bonetti F; Montagna D; Porta F; Lanfranchi A; Zecca M; Comoli P; Personeni A; Gritti G; Maccario R; DeStefano P
Leukemia; 1995 Apr; 9(4):570-5. PubMed ID: 7723386
[TBL] [Abstract][Full Text] [Related]
11. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation.
Hartmann O; Kalifa C; Benhamou E; Patte C; Flamant F; Jullien C; Beaujean F; Lemerle J
Cancer Chemother Pharmacol; 1986; 16(2):165-9. PubMed ID: 3512113
[TBL] [Abstract][Full Text] [Related]
12. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission.
Mehta J; Powles R; Singhal S; Horton C; Tait D; Treleaven J
Bone Marrow Transplant; 1996 Jul; 18(1):119-23. PubMed ID: 8832004
[TBL] [Abstract][Full Text] [Related]
13. Autologous bone marrow transplantation following high dose chemotherapy for the treatment of adult patients with acute myeloid leukaemia.
Goldstone AH; Anderson CC; Linch DC; Franklin IM; Boughton BJ; Cawley JC; Richards JD
Br J Haematol; 1986 Nov; 64(3):529-37. PubMed ID: 3539175
[TBL] [Abstract][Full Text] [Related]
14. Repeated high-dose-melphalan with autologous bone marrow transplantation in acute non lymphocytic leukemia.
Mascret B; Maraninchi D; Gastaut JA; Camerlo J; Novakovitch G; Perrimond H; Sebahoun G; Lepeu G; Rossi F; Carcassonne Y
Rev Fr Transfus Immunohematol; 1985 Nov; 28(5):477-88. PubMed ID: 3912925
[No Abstract] [Full Text] [Related]
15. Autologous bone marrow transplantation (ABMT) for acute leukaemia in complete remission: a pilot study of 33 cases.
Cahn JY; Herve P; Flesch M; Plouvier E; Noir A; Racadot E; Montcuquet P; Behar C; Pignon B; Boilletot A
Br J Haematol; 1986 Jul; 63(3):457-70. PubMed ID: 3524657
[TBL] [Abstract][Full Text] [Related]
16. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy.
Vincent MD; Powles TJ; Coombes RC; McElwain TJ
Cancer Chemother Pharmacol; 1988; 21(3):255-60. PubMed ID: 3282709
[TBL] [Abstract][Full Text] [Related]
17. Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy.
Phillips GL; Shepherd JD; Barnett MJ; Lansdorp PM; Klingemann HG; Spinelli JJ; Nevill TJ; Chan KW; Reece DE
J Clin Oncol; 1991 Oct; 9(10):1880-8. PubMed ID: 1919638
[TBL] [Abstract][Full Text] [Related]
18. Repeat administration of high dose melphalan in relapsed myeloma.
Mansi JL; Cunningham D; Viner C; Ellis E; Meldrum M; Milan S; Gore M
Br J Cancer; 1993 Nov; 68(5):983-7. PubMed ID: 8217614
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Gaspard MH; Maraninchi D; Stoppa AM; Gastaut JA; Michel G; Tubiana N; Blaise D; Novakovitch G; Rossi JF; Weiller PJ
Cancer Chemother Pharmacol; 1988; 22(3):256-62. PubMed ID: 3044633
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of high-dose continuous intravenous infusion of VP-16 in combination with high-dose melphalan followed by autologous bone marrow transplantation in children with stage IV neuroblastoma.
Valteau-Couanet D; Vassal G; Pondarré C; Bonnay M; Benhamou E; Couanet D; Plantaz D; Hartmann O
Bone Marrow Transplant; 1996 Apr; 17(4):485-9. PubMed ID: 8722343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
